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Abstract
Background: Heat shock protein 70 (Hsp70) was identified as a cellular interaction partner of the influenza virus
ribonucleoprotein (RNP) complex. The biological significance of the interaction between Hsp70 and RNP has not been fully
investigated.
Principal Findings: Here we demonstrated that Hsp70 was involved in the regulation of influenza A viral transcription and
replication. It was found that Hsp70 was associated with viral RNP by directly interacting with the PB1 and PB2 subunits, and
the ATPase domain of Hsp70 was required for the association. Immunofluorescence analysis showed that Hsp70 was
translocated from the cytoplasm into the nucleus in infected cells. Then we found that Hsp70 negatively regulated the
expression of viral proteins in infected cells. Real-time PCR analysis revealed that the transcription and replication of all eight
viral segments were significantly reduced in Hsp70 overexpressed cells and greatly increased as Hsp70 was knocked down
by RNA interference. Luciferase assay showed that overexpression of Hsp70 could inhibit the viral RNP activity on both
vRNA and cRNA promoters. Biochemical analysis demonstrated that Hsp70 interfered with the integrity of RNP.
Furthermore, delivered Hsp70 could inhibit the replication of influenza A virus in mice.
Significance: Our study indicated that Hsp70 interacted with PB1 and PB2 of RNP and could interfere with the integrity of
RNP and block the virus replication in vitro and in vivo possibly through disrupting the binding of viral polymerase with viral
RNA.
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Introduction
I n f l u e n z aAv i r u si sas i n g l e - s t r a n d e d ,n e g a t i v e - s e n s eR N A
virus with eight genomes, belonging to the family Orthomyxovir-
idae. In the nucleus, eight genomes are capsidated by multiple
copies of nucleoproteins and viral heterotrimeric polymerase
complex, including PA, PB1, and PB2. The complex, namely
viral RNP, is required for viral transcription and replication.
The transcription of vRNA is initiated by use of short capped
R N Ao l i g o n u c l e o t i d e sa sp r i m e rs which are snatched from host
cellular mRNA by viral polymerase. Such primers contain the
cap structure at the 59 ends followed by 9–15 nucleotides [1].
The transcription terminates at a sequence of five to seven
uridines located 15 to 17 nucleotides from the 59 end of vRNA
templates, where viral polymerase complex stutters by the
addition of poly(A) tail. In contrast, the replication includes the
intermediate complementary RNA synthesis which is positive-
sense RNA and serves as the template for synthesis of progeny
vRNA. The replication does not need primer and guarantees
the fidelity.
Though the transcription and replication are fulfilled by viral
polymerase complex, the three subunits of RNP have different
functions. PB1 subunit is the core of the complex and has the
polymerase activity [2,3], and vRNA and cRNA promoter binding
activities [4,5], while PB2 is responsible for cap recognition [6,7].
PA has multiple functions such as protease activity causing the
degradation of its associated partner and itself [8], endonuclease
activity [9,10], promoter binding activity [11,12], virus assembly
[13], and N-terminal of PA is involved in cap binding [14].
Some host factors are involved in replication and transcription
of the influenza virus genome [15]. RanBP5 was found to interact
with either PB1 or PA-PB1 heterodimer and help PA-PB1 dimer
to enter the nucleus to form PA-PB1-PB2 complex [16]. Ebp1 was
identified to interact with PB1 subunit and interfered with viral
RNA synthesis in vitro, indicating that it was an inhibitor of
influenza virus polymerase [17]. In addition, Hsp90 was identified
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or PB1-PB2 dimer and promoting them to enter the nucleus and
form the functional polymerase complex [18,19]. Additionally,
host factor CCT was identified as PB2 binding protein, and the
silencing of CCT reduced viral replication by reducing PB2
protein level and RNA accumulation [20].
Hsp70 is a molecular chaperone belonging to heat shock protein
family. It is a stress-inducible member, in contrast to Hsc70
expressed constitutively. Hsp70 plays important role in the folding
and assembly of newly synthesized proteins, refolding of misfolded
and aggregated proteins, membrane translocation of organellar
and secretory proteins, and controlling of the activities of
regulatory proteins [21,22,23,24]. Hsp70 consists of a N-terminal
ATPase domain and a C-terminal peptide binding domain (PBD)
in which there is EEVD motif enabling it to bind to co-chaperones
and other heat shock proteins such as Hsp90, Hsp40 and Hop
[25,26,27,28]. Hsp70 was found to inhibit virus infection
[29,30,31]. Nevertheless, some viruses could utilize Hsp70 to help
their own replication [32,33,34,35,36,37]. For influenza virus
Hsp70 was identified to be involved in regulation of viral life cycle.
Hsc70 interacted with M1 and the interaction was required for
viral production [38]. Hsp70 was found to bind to ribonucleo-
protein complex, which prevented M1 from binding to vRNP so
that the nuclear export of vRNP was inhibited [39]. Proteomic
data confirmed that Hsp70 was the interaction partner of
influenza virus ribonucleoprotein complex [40]. It was reported
that a higher level of Hsp70 was associated with vRNPs of
influenza A/Ann Arbor/6/60 virus which was defective in
replication compared with those of rWT virus [41]. However, it
is not clear whether the interaction between Hsp70 and RNP has
any effect on the polymerase activity.
In this study, we demonstrated that Hsp70 negatively regulated
influenza virus RNP activity. It interacted with PB1 and PB2
subunits of RNP and was translocated from the cytoplasm to the
nucleus in infected cells. Furthermore, Hsp70 interfered with the
integrity of RNP, and then negatively regulated the viral
transcription and replication.
Results
Hsp70 interacted with PB1 and PB2 subunits of RNP
It was known that Hsp70 was associated with RNP complex
[39,40]. To understand the significance of the association, we
examined which subunit(s) of RNP that Hsp70 interacts with.
293T cells were co-transfected by Myc-Hsp70 with FLAG-NP,
FLAG-PA, PB1cFLAG, or FLAG-PB2 plasmid, respectively. The
total cell extracts were prepared and immunoprecipitated with
anti-FLAG antibody followed by immunoblotting with anti-Myc
antibody. The result showed that Hsp70 interacted with PA, PB1,
and PB2 but not NP (Fig. 1A). We also examined whether
endogenous Hsp70 could interact with PA, PB1, and PB2 in
infected cells. 293T and MDCK cells were infected, and then the
total cell extracts were prepared and subjected to immunoprecip-
itation with anti-Hsp70 antibody and immunoblotting with anti-
PA, anti-PB1 or anti-PB2 antibody. The results showed that both
PB1 and PB2 (Fig. 1B, C) interacted with endogenous Hsp70 in
both cell lines. There was no detectable interaction between PA
and endogenous Hsp70 (data not shown).
GST pull-down assays were carried out to confirm the direct
interaction of Hsp70 with PB1 and PB2. As shown in Fig. 2A, B
Hsp70 interacted with PB1 (aa79-659) which included cRNA
promoter binding domain, part of vRNA promoter binding
domain, and RNA polimerization motif [5,42]. The data in
Fig. 2C, D illustrated that Hsp70 interacted with N-terminal
domain (aa1-521) of PB2 which included the NP binding domain
[43].
Hsp70 could be divided into two functional domains, the N-
terminal ATPase domain and the C-terminal protein binding
domain (PBD) in which there was EEDV motif (Fig. 2E). To
examine which domain of Hsp70 was required for its interaction
with PB1 and PB2, full length and truncated forms of Hsp70 were
generated for GST pull-down assay. As shown in Fig. 2F, the
ATPase domain was required for its direct interaction with PB1
(aa79-659) and PB2 (aa1-521).
Hsp70 was translocated into nucleus post-infection
The subcellular localization of Hsp70 during infection was
examined by immunofluorescence assay with A549 cells. Endog-
enous Hsp70 was mainly localized in the cytoplasm of non-
infected cells (Fig. 3D). In contrast, Hsp70 was translocated into
the nucleus at 2 h post-infection (Fig. 3E). The staining of NP
indicated the nuclear localization of viral polymerase complex
(Fig. 3B). NP was localized in the nucleus of most of cells at 4 h
post-infection (Fig. 3C), and colocalized with Hsp70 in the nucleus
(Fig. 3H, I). These results demonstrated that Hsp70 was
translocated into the nucleus and colocalized with viral polymerase
where the viral transcription and replication occurred. The same
result could also be reproduced with HeLa cells (data not shown).
Induction of Hsp70 with PGA1 inhibited the transcription
and replication of influenza A virus genomes
In order to understand the biological function of Hsp70 on
influenza virus replication, cells were infected, treated with PGA1,
which was known to induce the overexpression of Hsp70 as
reported [44]. The supernatants were harvested to examine the
viral titers by plaque assay at different time points post-infection.
The data showed that the viral titers in the supernatants from
PGA1-treated A549 cells were reduced at 8 h and 12 h post-
infection in comparison with the control (Fig. 4A), which was
consistent with the result of others [39]. The reduced M1 protein
level from the virion of the supernatants confirmed that the PGA1-
treatment caused the decrease of released virion (Fig. 4B, C).
We wondered if the effect of Hsp70 on the viral titers was due to
the decreased level of viral proteins. The total cell extracts were
prepared at indicated time points for immunoblotting with anti-
Hsp70, anti-M1, anti-NP, and anti-b-actin antibodies. The protein
level of Hsp70 increased as expected while both M1 and NP
protein levels were reduced in PGA1-treated A549 (Fig. 4D, E)
and MDCK (Fig. 4F, G) cells in comparison with those in
untreated cells.
To determine whether the inhibitory effect of PGA1 on viral
proteins level was due to the inhibition of the transcription and
replication of viral genomes, the amounts of mRNA, vRNA and
cRNA of eight genomes were measured. A549 cells were infected
and then treated with PGA1. The total RNAs were prepared at
8 h post-infection and the amounts of mRNA, vRNA, and cRNA
were quantified by real-time RT-PCR. The data showed that
mRNA, vRNA, and cRNA levels of all eight genomes were greatly
reduced in PGA1-treated cells (Fig. 5A, B, C). These results
indicated that PGA1 treatment inhibited viral transcription and
replication so as to reduce viral proteins level and viral titer.
The transcription and replication of influenza A virus
genomes were up-regulated in Hsp70 depleted cells
To confirm that the inhibitory effect of PGA1 on the viral
transcription and replication is indeed due to the induction of
Hsp70, we took the approach of RNA interference to knock down
Hsp70 Inhibits Influenza Virus Polymerase Activity
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replication. HeLa cells were used in this experiment because the
siRNA can efficiently knock down the expression of Hsp70 in this
cell line. HeLa cells were transfected with Hsp70 siRNA or control
siRNA, and then infected with influenza A virus for 7 h. Total
RNAs were isolated and subjected to real-time RT-PCR for
mRNA, vRNA and cRNA. The results showed that the mRNA,
vRNA, and cRNA levels of all eight genomes increased in Hsp70
Figure 1. Hsp70 interacts with PB1 and PB2 subunits of viral polymerase complex. (A) 293T cells were transfected with pCMV-Myc-Hsp70
and pcDNA3-FLAG-NP, pcDNA3-FLAG-PA, pcDNA3-PB1cFLAG, or pcDNA3-FLAG-PB2, with pcDNA3.1 as negative control. The total cell extracts were
immunoprecipitated with anti-FLAG antibody and immunoblotted with monoclonal anti-Myc antibody. (B, C) 293T cells and MDCK cells were infected
with rWSN at MOI of 1 for 24 h. Total cell extracts were immunoprecipitated with rabbit anti-Hsp70 antibody or normal rabbit serum (NRS) as control
and immunoblotted with goat anti-PB1 antibody (B) or goat anti-PB2 antibody (C). These experiments were repeated twice with identical results.
doi:10.1371/journal.pone.0016546.g001
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16546Figure 2. Hsp70 interacts with PB1 and PB2 directly. The GST-fused PB1 mutants (A, B) or GST-fused PB2 (C, D) mutants were generated. The
interaction between GST-PB1 mutants (B) or GST-PB2 mutants (D) and His-Hsp70 was analysed by GST pull-down assay and Western blot (upper
panel), the CBB staining of purified proteins were shown in lower panel. (A, C) Binding activity is indicated as ‘‘+’’, no significant binding activity as
‘‘2’’. (E) The schematic map of Hsp70 and its mutants. (F) His-Hsp70, His-Hsp70DEEVD, His-Hsp70 ATPase domain and His-Hsp70 PBD were prepared
and subjected to GST pull-down assays with GST-PB1(79–659) (upper left panel), GST-PB2(1–521) (upper right panel) and GST as negative control, and
the purified His-Hsp70 and its mutants were subjected to CBB staining (lower panel). Arrows indicated purified proteins of CBB staining. These
experiments were repeated twice with identical results.
doi:10.1371/journal.pone.0016546.g002
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Consistently the protein levels of M1 and NP also increased in
Hsp70-depleted cells (Fig. 6A, B). These results suggested that
knockdown of Hsp70 favored viral transcription and replication.
Hsp70 inhibited both transcription and replication of
RNP
The primary transcription of input vRNP initiates when host
cell is infected with influenza virus, followed by the replication
producing progeny vRNP which is used to carry on subsequent
secondary transcription. Since mRNA, vRNA, and cRNA levels
increased in Hsp70-depleted HeLa cells, we wondered whether the
increased mRNA level was caused by increased progeny vRNA or
the direct effect of Hsp70 on primary transcription of input vRNP.
It has been reported that cycloheximide (CHX), an inhibitor of
protein synthesis, inhibited the transition from primary transcrip-
tion to replication [45], therefore we could examine whether
Hsp70 affect the primary transcription by using CHX to block the
synthesis of progeny vRNP. CHX treatment did not affect the
knockdown of endogenous Hsp70 in HeLa cells (Fig. 7A), then
real-time RT-PCR results showed that the amounts of mRNA of
NP and NS segments increased 2–3 fold in the presence of CHX
and 4–5 fold in the absence of CHX in Hsp70 depleted HeLa cells
(Fig. 7B). These data indicated that removing Hsp70 in the
absence of replication caused the increase of mRNA level, but the
increase was higher if both transcription and replication occured,
suggesting that Hsp70 negatively regulated both transcription and
replication.
Hsp70 inhibited the activity of the influenza virus
polymerase in a dose-dependent manner
To examine whether Hsp70 could regulate the activity of
influenza virus polymerase, we took the approach of luciferase
assay with vRNA and cRNA promoters. 293T cells were co-
transfected with multiple plasmids as followed (i) the expression
vectors encoding influenza virus polymerase subunits and NP; (ii)
pHH21-vNS-Luc or pHH21-cNS-Luc reporter plasmid; and (iii)
pCMV-Myc-Hsp70 in different doses or pcDNA3.1 as negative
control. The cell lysates were subjected to luciferase assay and
Western blot. The data of luciferase assay showed that relative
luciferase activities under both vRNA and cRNA promoters in
Hsp70 overexpressed cells were much lower than those in control
cells in a dose-dependent manner (Fig. 8A), which indicated that
Hsp70 inhibited the activity of viral polymerase complex on both
vRNA and cRNA promoters. The immunoblotting results showed
that the levels of RNP proteins were similar in the cells transfected
with or without Myc-Hsp70 (Fig. 8B).
To examine which domain of Hsp70 was required for the
inhibitory effect, we generated the truncated forms of Hsp70 and
performed luciferase assay. The data showed that ATPase domain
Figure 3. Hsp70 is translocated into the nucleus in infected A549 cells. A549 cells were infected with rWSN at MOI of 5 for 1 h and cultured
for indicated time. The infected and noninfected A549 cells were fixed and stained with rat anti-NP antibody (A, B and C) and rabbit anti-Hsp70
antibody (D, E and F), colocalization of Hsp70 and NP were shown in merged images (G, H and I), and DAPI staining indicated the nucleus (J, K and L).
doi:10.1371/journal.pone.0016546.g003
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the activity of viral polymerase but EEVD motif was not required
(Fig. 8C). The immunoblotting data showed that the expression of
RNPsubunitsand truncatedformsofHsp70intransfected cellswere
similar except that the expressions of PA and PB2 were higher in
Myc-Hsp70 ATPase-transfected cells (Fig. 8D).
Hsp70 interfered with the integrity of RNP
The viral polymerase complex consists of PA, PB1 and PB2, in
which PB1 and PB2 interacted with Hsp70 (Fig. 1). Furthermore the
binding regions of PB1 and PB2 with Hsp70 (Fig. 2) were pivotal to
the RNP functions. We speculated that Hsp70 might affect the
integrity of RNP. To test this idea, the MDCK cells were infected
with virus and the nuclear fraction was isolated and incubated with
His-Hsp70 or BSA as negative control. Then the mixtures were
subjected to glycerol gradient centrifugation. The fractions were
collected and subjected to immunoblotting with anti-NP, anti-PA,
anti-PB2 and anti-Hsp70 antibodies (Fig. 9A) as well as semiquan-
titative RT-PCR for vRNA and cRNA of NP segment (Fig. 9B). As
shown in Fig. 9A, in BSA-treated RNPs PA sedimented predom-
inantly in fractions 1 to 7, PB2 in fractions 1 to 9, NP in almost all
fractions except fraction 12, then in Fig. 9B vRNA and cRNA
sedimented in fractions 1 to 8, therefore, it was shown that RNP
complex sedimented to fractions 1 to 7, because there existed vRNA
(cRNA), NP, PA and PB2. In contrast, in Hsp70-treated RNPs
vRNA and cRNA sedimented mainly in fractions 6 to 9, NP in
fractions 6 to 10, but PA and PB2 in fractions 1 to 4 where Hsp70
sedimented. We concluded that the addition of Hsp70 disrupted the
Figure 4. PGA1 treatment inhibits the propagation of influenza A virus. Cells were infected with rWSN at MOI of 1, then cultured in the
absence or presence of PGA1 for the indicated intervals. The supernatants and total cell extracts were harvested. (A) The supernatants from infected
A549 cells were subjected to plaque assay to measure the viral titers shown as the data on the bars. Error bars represent standard deviation (n=3). (B,
C) M1 protein (SN) and Hsp70 (TCE) were detected by immunoblotting (B) with mouse anti-M1 and rabbit anti-Hsp70 antibodies (SN and TCE stand
for supernatant and total cell extract, respectively). (C) The relative quantification of M1 in (B). (D–G) Total cell extracts of infected A549 cells (D, E) and
MDCK cells (F, G) were prepared for immunoblotting with rabbit anti-Hsp70, rat anti-NP, mouse anti-M1, and rabbit anti-b-actin antibodies (D, F). (E,
G) The relative quantification of M1 and NP in (D, F).
doi:10.1371/journal.pone.0016546.g004
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PA and PB2 were not in the same fractions.
Hsp70 inhibited influenza A virus replication in vivo
In order to investigate whether Hsp70 protein inhibits influenza
virus replication in vivo, we prepared the TAT-Hsp70 protein for
virus infection assay. It had been reported that TAT-Hsp70 was able
to be delivered into cells and mice efficiently [46,47]. We examined
the effect of TAT-Hsp70 on viral infection in BALB/c mice.
Preliminary experiments with mice infection showed that TAT-
Hsp70 protein had not exerted any effect on the virus when they were
mixed before intranasal infection (data not shown). On day 3 post-
infection the viral lung titers of the TAT-Hsp70-treated mice were
much lower than those of control mice treated with PBS or TAT-
GFP, 7.21610
4, 4.12610
4 a n d3 3P F U / 0 . 2gl u n gi nP B S ,T A T -
GFP and TAT-Hsp70-treated mice respectively. As shown in
Fig. 10C, the body weights of control groups and TAT-Hsp70-
treated group have diverged significantly on day 3 post-infection. The
survival and body weight were examined daily post-infection. All of
TAT-Hsp70-treated mice survived while all of PBS or TAT-GFP-
treated mice died on the ninth or tenth day respectively (Fig. 10B).
The body weight of TAT-Hsp70-treated group increased but those of
control groups declined greatly (Fig. 10C). These results showed that
Hsp70 protein could effectively inhibit virus propagation in mice and
protect the mice from influenza virus infection.
Discussion
In this study, we revealed a distinct mechanism of Hsp70-
mediated regulation of influenza virus polymerase activity.
Figure 5. Hsp70 negatively regulates influenza virus RNA transcription and replication. (A, B, C) A549 cells were infected with rWSN at
MOI of 1, and then cultured in the absence or presence of PGA1 for 8 h. The cells were harvested and the total RNAs were isolated with TRIzol
reagent, then mRNA (A), vRNA (B) and cRNA (C) of eight genomes were quantified by real-time RT-PCR as described in Materials and Methods. The
white bars of nontreated samples are set to a relative value of 1, and the black bars are expressed as relative value compared with control. (D, E, F)
HeLa cells were transfected with Hsp70 siRNA or control siRNA for 60 h and infected with rWSN at MOI of 1 for 7 h. The total RNAs were isolated and
quantified by real-time RT-PCR for viral mRNA (D), vRNA (E) and cRNA (F) of eight genomes. The white bars of control siRNA-transfected cells are set
to a relative value of 1, and the black bars represent the relative value compared with control. The data represent the means of three independent
experiments, each performed in triplicate. Error bars represent standard deviation (n=3).
doi:10.1371/journal.pone.0016546.g005
Figure 6. The influenza virus proteins level is increased in Hsp70 depleted cells. HeLa cells were transfected with Hsp70 siRNA or control
siRNA and infected with rWSN for 7 h. Total cell extracts were prepared for immunoblotting with indicated antibodies (A), and the amount of proteins
were quantified (B).
doi:10.1371/journal.pone.0016546.g006
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propagation through blocking the nuclear export of ribonucleo-
protein complex [39]. In light of these and our current findings,
Hsp70 may have multiple mechanisms of controlling the viral
replication during virus infection. Although more studies are
needed to understand the detailed regulatory mechanisms of
Hsp70 in viral replication, our findings revealed the novel role of
Hsp70 in regulating viral polymerase activity by interfering with
the integrity of RNP.
Co-immunoprecipitation assays showed that Hsp70 could
interact with PA subunit of influenza virus polymerase in cells
transfected with Hsp70 and PA (Fig. 1A) but the interaction
between Hsp70 and PA was undetectable in infected 293T and
MDCK cells. The reason may be that the interaction between PA
and Hsp70 was relatively weak and the amount of PA protein was
much lower in infected cells than that in transfected cells so it was
hard to detect the interaction between them. Therefore further
experiments such as GST pull-down assay were required to
confirm their interaction.
The endogenous Hsp70 was located in cytoplasm [48]. In
infected cells Hsp70 was translocated into nucleus where the viral
transcription and replication occurred (Fig. 3). Therefore there
was spatial possibility for Hsp70 to regulate the viral transcription
and replication. But the exact mechanism of how Hsp70 was
translocated into nucleus needs further elucidation.
Our results confirmed that Hsp70 interacted with PB1 and
PB2 subunits both in vitro and in vivo (Fig. 1 and Fig. 2). We
wondered how Hsp70 inhibited the function of RNP complex.
Therefore we examined whether Hsp70 affected the integrity of
RNP. The data in Fig. 9A, B showed that Hsp70 interfered with
the binding of NP and vRNA (cRNA) with viral polymerase
complex. In vitro GST pull-down assays affirmed that Hsp70 did
not affect the binding of NP with PB1 and PB2 (data not shown).
Furthermore, it was reported that PB1 bound to the vRNA and
cRNA promoter [4,5]. GST pull-down data (Fig. 2A) indicated
that Hsp70 bound to vRNA and cRNA promoter binding
domains of PB1. Therefore we speculated that Hsp70 disrupted
the integrity of RNPs through interfering the binding of PB1 with
viral RNA promoter so that viral RNA and RNA-bound NP fell
off from the polymerase complex as shown in Fig. 9. Taken
together, the results indicated that Hsp70 interfered with the
integrity of RNP most likely by blocking the interaction of PB1
with vRNA (cRNA) rather than the association of NP with PB1
and PB2.
Inconsistently with our findings, Dalton RM reported that
Hsp70 was not responsible for down-regulation of viral RNAs
synthesis by using quercetin to inhibit Hsp70 synthesis [49],
Quercetin has been proved to be involved in many cellular
pathways in addition to the inhibition of Hsp70 synthesis. For
example, quercetin inhibited NF-kB pathway [50]. It has been
reported that NF-kB signaling regulated influenza virus RNA
synthesis [51], so quercetin may inhibit viral RNAs synthesis by
the inhibition of NF-kB pathway. Therefore, quercetin treatment
in influenza virus infected cells may produce the counteractive
effect on viral RNAs synthesis through Hsp70 and NF-kB
pathway, or other unknown pathways, that may be the reason
why Dalton, R. M. did not observe the effect of quercetin
treatment on viral RNAs level.
Nowadays although there are some anti-influenza drugs
available, but drug resistants emerged rapidly after therapeutic
use in influenza virus infection [52]. It is necessary to develop new
drugs against influenza virus. The peptide originated from viral
protein as antiviral agent has been studied recently. It was
reported that PB11–25 peptide could inhibit the influenza virus
polymerase activity [53], and the zinc finger peptide of M1(aa148–
166) could block the propagation of influenza virus in mice [54].
Since the viral protein as a foreign protein may bring up side effect
of immunoreactivity when being delivered in vivo, it will be better
to use host factors as anti-influenza agents. It has been reported
that Hsp70 induced by delta
12-PGJ2 or PGA2 could inhibit
influenza virus in vivo [55,56]. It was known that prostaglandins
could activate heat shock transcription factor which increased the
transcription of both Hsp70 and Hsp90 [57]. But Hsp90 was
Figure 7. Hsp70 inhibits both transcription and replication of
RNPs. HeLa cells were transfected with Hsp70 siRNA and control siRNA
for 60 h and infected with rWSN in the presence of 100 mg/ml of CHX
for 1 h then cultured with DMEM containing CHX for 7 h, or in the
absence of CHX as control. Total cell lysates were prepared for
immunoblotting with anti-Hsp70 and anti-b-actin antibodies (A). Total
RNA was isolated and subjected to real-time RT-PCR to measure the
amounts of mRNA of NP and NS segments. The white bars of control
siRNA-transfected cells are set to a relative value of 1, and the black bars
represent the relative value campared with control (B). The data
represent the means of three independent experiments, each
performed in triplicate. Error bars represent standard deviation (n=3).
doi:10.1371/journal.pone.0016546.g007
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prostaglandins were not ideal for anti-influenza drug. Recently
TAT peptide was used to deliver exogenous protein into cultured
cells and mice [58,59], and it had no effect on influenza virus
replication [60]. So we took the approach of TAT peptide
mediated transduction method to deliver Hsp70 into mice and
found that Hsp70 could inhibit the propagation of influenza virus
in vivo. It was the first report that host protein was utilized as
influenza virus inhibitor in vivo.
In conclusion, we demonstrate that Hsp70 is the inhibitory host
factor for influenza virus by interfering with the viral polymerase
activity. Our further research will be focused on the development
of inhibitory peptide based on Hsp70 protein and providing the
candidates for new anti-influenza drugs.
Materials and Methods
Plasmid construction
Hsp70 gene was amplified fromhuman cDNA library by PCR and
cloned into pCMV-Myc (Clonetech) and pET28c (Novagen). The
truncated mutants of Hsp70 (DEEVD, aa1-611; ATPase domain,
aa1-385; PBD, aa386-641) were inserted into pCMV-Myc and
pET28c vectors. NP, PA and PB2 were cloned into pcDNA3-FLAG,
and PB1cFLAG was inserted into pcDNA3.1 (Invitrogen) to generate
expression vector for C-terminal FLAG-tagged PB1. The truncated
mutants of PB1 and PB2 were cloned into pGEX-4T-2 (Amersham
Pharmacia Biotech). pHH21-vNS-Luc was polymerase I expressing
plasmid carrying an influenza virus-like RNAcodingfor theluciferase
reporter protein (kindly provided by Martin Schwemmle, University
Figure 8. Hsp70 inhibits influenza virus polymerase activity in a dose-dependent manner. (A, B) 293T cells were transfected with pHH21-
vNS-Luc (left panel) or pHH21-cNS-Luc (right panel), NP, PA, PB1, PB2 expression plasmids, and 50 ng, 100 ng, 200 ng of pCMV-Myc-Hsp70 or 200 ng
of pcDNA3.1 as negative control, then subjected to luciferase assay (A) and immunoblotting with indicated antibodies (B). (C) 293T cells were
transfected with pHH21-vNS-Luc (left panel) or pHH21-cNS-Luc (right panel), plasmids encoding NP, PA, PB1, PB2, and 200 ng of pCMV-Myc-Hsp70,
pCMV-Myc-Hsp70DEEVD, pCMV-Myc-Hsp70 ATPase domain, pCMV-Myc-Hsp70 PBD or 200 ng of pcDNA3.1 as negative control. The luciferase assays
were performed accordingly. The data represent the means of two independent experiments, each performed in triplicate. Error bars represent
standard deviation (n=3). (D) The protein levels were analysed by immunoblotting with indicated antibodies.
doi:10.1371/journal.pone.0016546.g008
Hsp70 Inhibits Influenza Virus Polymerase Activity
PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e16546of Freiburg) [53]. pHH21-cNS-Luc was generated by cloning cRNA
promoter of NS with luciferase into pHH21.
Cell lines, virus and antibodies
Madin-Darby Canine Kidney (MDCK) cells, human embryo
kidney 293T cells, human lung adenocarcinoma epithelial cell line
(A549) and HeLa cells were maintained at 37uC in Dulbecco’s
Modified Eagle’s medium (DMEM, Gibco) supplemented with
10% heat-inactivated fetal bovine serum (FBS, PAA). The
recombinant influenza virus A/WSN/33 (rWSN) was generated
by 12 plasmids system as described previously [61]. Rabbit anti-
Hsp70 and anti-PA antibodies were generated by immunizing the
rabbits with GST-Hsp70 (aa618-633) and GST-PA (aa1-256),
respectively, then affinity purified. Monoclonal anti-Myc (9E10)
and anti-His antibodies, goat anti-PB1 (sc-17602), goat anti-PB2
(sc-17603) and rabbit anti-b-actin (sc-1616) antibodies were
purchased from Santa Cruz Biotechnology. Mouse anti-FLAG
(M2) antibody was purchased from Sigma. Mouse anti-M1
monoclonal antibody was prepared as described previously [62],
Rat anti-NP antibody (generously provided by Wenjun Liu,
Institute of Microbiology, Chinese Academy of Sciences) was
generated by immunizing the rat with His-NP protein.
Virus infection
Monolayer cultured cells were washed twice with PBS, and then
infected with rWSN at an indicated multiplicity of infection (MOI).
After virus adsorbtion for 1 h at 37uC, the cells were washed twice
withPBSand incubatedat 37uC withculture medium.As forPGA1
treatment, the cells were incubated with 20 mg/ml PGA1 (Sigma) in
DMEM post-infection and harvested at indicated time.
Plaque assay
MDCK monolayer cells in 35-mm dishes were washed with
PBS, and serial dilutions of virus were adsorbed onto cells for 1 h.
Unadsorbed virus was removed by washing with PBS, then
monolayer cells were overlaid with DMEM supplemented with
3% low-melting-point agarose and 2 mg/ml TPCK-treated trypsin
(Sigma). Visible plaques were counted and viral titers were
Figure 9. Hsp70 interferes with the integrity of RNP. (A, B) MDCK cells were infected with rWSN, and then subjected to cell fractionation. The
nuclear fraction was incubated with His-Hsp70 or with BSA as control, and then applied to a glycerol gradient. Fractions (1 to 12) were collected from the
top to the bottom. An aliquot of each fraction was subjected to immunoblotting with indicated antibodies (A). RNA was purified from each fraction, and
reverse transcribed into cDNA with primer specific for vRNA or cRNA. ThecDNA was thensubjected tosemiquantitative PCR withprimers for NP. ThePCR
products were subjected to 1% agarose gel and visualized by ethidium bromide (B). These experiments were repeated three times with identical results.
doi:10.1371/journal.pone.0016546.g009
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PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e16546Figure 10. Hsp70 inhibits influenza virus replication in vivo. Four-week-old female BALB/c mice were infected rWSN plus PBS, TAT-GFP or
TAT-Hsp70, and then injected intraperitoneally with PBS, TAT-GFP or TAT-Hsp70 daily from day 1 to 6 post-infection. Three mice from each group
were sacrificed on day 3 post-infection, the viral titers in lungs were analysed by plaque assay (A). The survival (B) and body weight (C) of the
remaining mice were monitored daily. Asterisk indicates a P value of,0.01 for viral titer comparing TAT-Hsp70 treated group to PBS and TAT-GFP
treated groups. Experiments were performed twice with identical results. Error bars represent standard deviation (n=3).
doi:10.1371/journal.pone.0016546.g010
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the mean of triplicated samples.
Transient transfection
293T cells were grown in 60-mm dishes at 80% confluence and
transfected with plasmids using Lipofectamine 2000 transfection
reagent (Invitrogen). The medium was replaced with fresh culture
medium at 7 h post-transfection.
Luciferase assay
293T cells were transiently transfected with plasmids expressing
influenza virus NP, PA, PB1, PB2 (100 ng for each) and pHH21-
vNS-Luc or pHH21-cNS-Luc (50 ng) with pCMV-b-gal plasmid
(50 ng) as control of transfection efficiency. The cell lysates were
harvested at 36 h post-transfection and subjected to luciferase
assay with Luciferase Assay System (Promega).
Co-immunoprecipitation assay
Transfected or infected cells were washed twice with cold PBS
and lysed in lysis buffer (1% TritonX-100, 150 mM NaCl, 20 mM
HEPES pH 7.5, 10% Glycerol, 1 mM EDTA) with protease
inhibitor cocktail (Roche) for 20 min, then centrifuged at
12,000 rpm at 4uC for 10 min. The supernatants were incubated
with indicated antibody at 4uC for 1 h, then the protein A-
Sepharose beads wereadded and rotatedat 4uC for 3 h and washed
with lysis buffer. The bound proteins were eluted by boiling with
SDS loading buffer for 5 min and subjected to Western blot.
GST pull-down assay
GST-fused PB1 or PB2 and the corresponding truncated
mutants were bound onto glutathione-Sepharose beads (GE
Healthcare), then mixed with His-Hsp70 or its mutants in lysis
buffer at 4uC for 60 min, the beads were washed with lysis buffer,
and the bound proteins were seperated by SDS-PAGE followed by
Western blotting with monoclonal anti-His antibody.
RNA interference
RNA interference was carried out using siRNA purchased from
Invitrogen. The siRNA corresponding to the Hsp70 mRNA
sequences 59-UGC ACC UUG GGC UUG UCU CCG UCG U-
39 was used to inhibit endogenous Hsp70 protein expression.
Control siRNA sequence was 59-UGC GUC GUC GAU CGC
UUA CUC UCG U-39. Transfection of siRNA into HeLa cells
was performed according to the manufacturer’s instructions. In
brief, HeLa cells at 50% confluence were transfected with 40 nM
siRNA using the Lipofectamine 2000.
Immunofluorescence
A549 cells were plated on glass coverslips and infected with
virus. At indicated time after infection, the cells were fixed with
4% paraformaldehyde for 10 min and permeabilized with 1%
TritonX-100 in PBS for 10 min. Then the cells were incubated
with rat anti-NP and rabbit anti-Hsp70 antibodies at 37uC for 1 h,
washed with 0.5% NP-40 in PBS and incubated with TRITC-
conjugated donkey anti-rabbit antibody and FITC-conjugated
goat anti-mouse antibody for 1 h, then stained with 2 mg/ml 49,
69-diamidino-2-phenylindole dihydrochloride (DAPI). The cells
were mounted and observed under confocal microscope (Leica).
Glycerol density gradient centrifugation
MDCK cells were infected with rWSN at MOI of 10 for 1 h
and cultured for 6 h, then the cells were harvested and incubated
in hypotonic lysis buffer (10 mM Tris, pH 8.0, 10 mM NaCl,
3 mM MgCl2, and 1 mM EGTA with protease inhibitors and
RNase Inhibitor) for 10 min, followed by 20 strokes of a Dounce B
homogenizer. The lysates were spun down for 5 min at 500 g, and
the nuclear pellet was washed three times in wash buffer
(hypotonic lysis buffer with 0.1% Nonidet P-40) and then treated
with nuclear lysis buffer (20 mM HEPES, pH 8.0, 25% glycerol,
0.42 M NaCl, 1.5 mM MgCl2, and 0.2 mM EDTA with a
mixture of protease and RNase inhibitors) for 30 min. The sample
was spun at 14,000 g for 30 min, and the supernatant was
designated as the nuclear fraction. The nuclear fraction was
incubated with 20 mg of His-Hsp70 at 4uC for 1 h or BSA as
negative control, and then loaded onto one step glycerol gradient
(1 ml of 70%, 0.75 ml of 50%, 0.375 ml of 40% and 1.8 ml of
33% (wt/vol) glycerol). The gradients were centrifuged at
39,000 rpm for 4 h at 4uC in a SW40Ti rotor (Beckman).
Fractions (300 ml) were collected from top to bottom.
Quantitative real-time RT-PCR
Total RNA was extracted from cells by TRIzol Reagent
(Invitrogen) according to the instruction. The reverse transcription
was carried out using sense-specific oligonucleotides for vRNA (59
AGC GAA AGC AGG 39 and 59 AGC AAA AGC AGG 39),
cRNA (59 AGT AGA AAC AAG G 39), and mRNA [oligo(dT)18].
A glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific
primer (59 GAT GCA GGG ATG ATG TTC 39) was also
included in the RT reaction mixture for vRNA and cRNA. The
quantitative real-time PCR was carried out in 20 ml reaction of a
mixture containing primers for each of the eight RNA segments
[51] or GAPDH (sense primer 59 TGC ACC ACC AAC TGC
TTA G 39, antisense primer 59 GAT GCA GGG ATG ATG
TTC 39) with SYBR green DNA dye (TOYOBO). The amount of
viral RNA, expressed as threshold cycle (CT) values, was
normalized by the amount of GAPDH RNA. Primers of
semiquantitative RT-PCR for NP gene: sense primer is 59-
CAGATACTGGGCCATAAGGAC-39 and antisense primer is
59-TTGTCTCCGAAGAAATAAG-39
Mice and virus infection
TAT was designated as YGRKKRRQRRR, 11-amino-acid
peptide of human immunodeficiency virus (HIV) TAT protein.
TAT-Hsp70 and TAT-GFP [58,59] were amplified by PCR, inserted
into pET28c, expressed in E. coli strain BL21 (DE3) pLysS and
purified. Specific-pathogen-free four-week-old female BALB/c mice
were used in the studies. Experiments were performed in accordance
with the institutional guidelines. Mice were divided into three groups
(15/each group). On day 0, mice were anesthetized with ether and
infected intranasallywith 10
4PFUof rWSNmixed with 200 mlo fP B S
(group 1), TAT-GFP (group 2) or TAT-Hsp70 (group 3) (1 mg/ml).
From day 1 to day 6, mice were injected intraperitoneally once a day
with 200 ml of PBS (group 1), TAT-GFP (group 2) or TAT-Hsp70
(group 3) (1 mg/ml). Three mice from each gro u pw e r es a c r i f i c e do n
day3 post-infection, and viraltitersinlung were determined byplaque
assay. The remaining 12 mice in each group were examined daily for
their body weight and survival.
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